Sacit Karamürsel
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Importance There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN. Objective To present the long-term efficacy and safety of patisiran in adults with hATTR-PN. Design, Setting, and Participants This global open-label extension (OLE) of the APOLLO randomized clinical trial and phase 2 OLE study enrolled patients from 43 hospitals or clinical centers across 19 countries between July 2015 and August 2017, with follow-up until November 2022. Of 212 eligible patients with hATTR who completed the phase 3 APOLLO or phase 2 OLE parent studies, 211 enrolled in and 138 completed the global OLE. Intervention Patisiran, 0.3 mg/kg, intravenously once every 3 weeks for up to 5 years. Main Outcomes and Measures Outcomes evaluated at year 5 of the global OLE included disability (polyneuropathy disability [PND] score); polyneuropathy severity (Neuropathy Impairment Score [NIS]), nutritional status (modified body mass index [mBMI]), quality of life (Norfolk Quality of Life–Diabetic Neuropathy [Norfolk QOL-DN]), and Rasch-Built Overall Disability Scale (R-ODS), with no statistical hierarchy. Safety, survival probability, and mortality were also assessed. Results At the global OLE baseline, the mean (SD) age was 61.3 (12.3) years, and 156 patients (73.9%) were male. In 138 patients completing the study, PND scores remained stable or improved in 89 patients (65.0%), NISs showed a mean (SD) change of 10.9 (14.7), and mean (SD) mBMI (calculated as weight in kilograms divided by height in meters squared times serum albumin in grams per liter) increased by 46.4 (120.7) over 5 years from baseline. Norfolk QOL-DN and R-ODS scores showed mean (SD) changes of 4.1 (16.7) and –3.7 (6.2), respectively. Adverse events (AEs) leading to study withdrawal occurred in 47 patients (22.3%). Infusion-related reactions were the most common treatment-related AE (n = 34 [16.1%]). Overall, 41 patients (19.4%) died during the study. Patisiran treatment in the parent study and low familial amyloid polyneuropathy score at parent study baseline were associated with significantly improved survival. Conclusions and Relevance In the longest study of an RNAi therapeutic for any disease, patisiran treatment resulted in modest changes for patients with hATTR-PN with an acceptable safety profile. These results highlight the importance of initiating early treatment for hATTR and the potential of RNAi therapeutics in medicine. Trial Registration ClinicalTrials.gov Identifier: NCT02510261
Year:
2025
Year:
2024
Aim: Prospective memory (PM) has an immense role in the activities of daily living and deficits of PM are common in various neuropsychiatric disorders. Transcranial direct current stimulation (tDCS) is a neuromodulatory technique that yields favorable outcomes yet only a few studies concerning PM with hindering results exist. The present double-blind cross-over randomized sham-controlled study aimed to assess the effect of a single-session of left-righr/sham tDCS over the prefrontal cortex on event-related PM in healthy individuals. Materials and Methods: 24 participants were administered a single session of 2 mA 20-minute left/right anodal or sham tDCS segregated by 7 days. An event-based PM task was utilized before and after tDCS every week to evaluate PM. Results: No effects of tDCS on PM were found. Conclusion: The present results argue against the effect of a single-session of tDCS over the prefrontal cortices on event-related PM. TDCS studies adopting divergent parameters are required.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (6)
Stefanie Geisler
Associate Professor
Washington University in Saint Louis School of Medicine
Mitsuharu Ueda
Kumamoto University
Serkan Aksu
University of Florida College of Public Health and Health Professions
Sashka Georgieva Zhelyazkova
Assistant professor
medical university of sofia
Dominique Deplanque
Professor of medical Pharmacology
Université de Lille
Céline Labeyrie
INSERM
Make your next move.
Prepare your application
Review drafts before you send them.